{"pub": "thehill", "url": "https://thehill.com/policy/healthcare/466980-drug-companies-spend-millions-on-lobbying-as-congress-tries-to-reign-in", "downloaded_at": "2019-10-23 08:30:58.587150+00:00", "title": "Drug companies spend millions on lobbying as Congress tries to rein in high drug prices", "language": "en", "text": "Prescription drug companies and trade groups shelled out millions of dollars to lobby Congress as it considered legislation aimed at reining in skyrocketing drug prices, according to new lobbying disclosure reports.\n\nThe Pharmaceutical Research and Manufacturers of America (PhRMA) \u2014 the trade group representing branded drug companies \u2014 spent $6.2 million on lobbying in the third quarter of 2019, which ran from July through the end of September.\n\nThat's $240,000 more than it spent during the same time frame last year.\n\nBipartisan members of Congress have worked all year on proposals aimed at curbing rising drug prices as polls show voters are increasingly worried about the issue.\n\nPhRMA lobbied on dozens of bills related to the industry, according to the reports, including one proposed by Speaker Nancy Pelosi Nancy PelosiOvernight Health Care \u2014 Presented by Partnership for America's Health Care Future \u2014 Four companies reach 0M settlement in opioid lawsuit | Deal opens door to larger settlements | House panel to consider vaping tax | Drug pricing markup tomorrow Schiff punches back after GOP censure resolution fails Trump urges GOP to fight for him MORE (D-Calif.) that would let the government negotiate the prices it pays for prescription drugs through Medicare.\n\nThe industry has pushed back fiercely on the proposal, calling it government \"price-setting\" that would kill drug innovation.\n\nPrescription drug companies have also sharply increased their lobbying amid a flurry of legislation targeting the industry.\n\nGilead, the maker of HIV drug Truvada, spent $1.5 million on its lobbying efforts in the third quarter of 2019, a 117 percent increase over what it spent during the same time frame last year.\n\nGilead has faced criticism for pricing Truvada at about $20,000 a year.\n\nSeveral drug companies, including Amgen and Bayer, also lobbied on bills that would allow the importation of cheaper drugs from other countries, a proposal that is opposed by the industry.\n\nAmgen, whose drugs treat chronic illnesses, spent $3 million in the third quarter, a 16 percent increase over what it spent in the same time frame last year.\n\nMeanwhile, Bayer, the maker of a top-selling prescription blood thinner, spent $2 million on lobbying in the third quarter, a 32 percent increase over what it spent during the same time frame last year.\n\nDrug companies, including AbbVie, are also lobbying on a proposal from the Trump administration that would tie what the U.S. pays for drugs to what other countries pay.\n\nAbbVie spent $1.8 million on lobbying in the third quarter of 2019, a nearly 200 percent increase from what it spent in the same time frame last year.\n\nSanofi, which has been under fire over the rising costs of insulin, spent $1.7 million on lobbying in the third quarter, an increase of 105 percent from what it spent during the same time frame last year.\n\nSome drug companies decreased the amount they spent on lobbying.\n\nPfizer spent $1.6 million in the third quarter, compared to the $2.9 million it spent in the same time frame last year.\n\nMeanwhile, Eli Lilly spent $1.4 million on lobbying in the third quarter, a drop of $560,000 from the same time frame last year.", "description": "Prescription drug companies and trade groups shelled out millions of dollars to lobby Congress\u00a0as it\u00a0considered legislation\u00a0aimed at reining in skyrocketing drug prices, according to new lobbying disclosure reports.", "authors": [], "top_image": "https://thehill.com/sites/default/files/prescriptiondrugspills_getty.jpg", "published_at": "2019-10-22"}